Page 4 - Exosome Sciences News Today

7 Molecular Diagnostics Recent Developments 7.1 Recent Developments - Importance and How to Use This Section 7.1.1 Importance of These Developments 7.1.2 How to Use This Section 7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx 7.3 Invitae to Acquire Genosity for $200M 7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test 7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience 7.6 Natera Revenues Grow 35 Percent 7.7 AnchorDx Closes $40M Financing Round 7...

3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Biocartis Collaborating With GeneproDx, Endpoint H...

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic tr...

Share this article Share this article ResearchAndMarkets.coms offering. Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cell types f...

Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for thi...

Press release content from Business Wire. The AP news staff was not involved in its creation. Global Mesenchymal Stem Cells Advances and Applications Market Report 2021 - ResearchAndMarkets.com February 12, 2021 GMT DUBLIN--(BUSINESS WIRE)--Feb 12, 2021-- As the most common stem cell type being used within regenerative medicine today, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well as over 1...

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 10, 2021 News provided by Share this article Share this article SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2021, ended December 31, 2020, at 4:15 p.m. EST on Wednesday, February 10, 2021. Management will ...

3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Impact of NGS on pricing 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Liquid Biopsy Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Liquid Biopsy NGS Panels - Diverse Test Claims CMS Colon Cancer Screening Me...

Liquid Biopsy Markets, 2025 with Impact of COVID-19 Pandemic February 02, 2021 04:43 ET | Source: Research and Markets Research and Markets Dublin, IRELAND ResearchAndMarkets.coms offering. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitor...

Share this article Share this article SAN DIEGO, Dec. 16, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the first patient has been treated in the Companys first-in-human Early Feasibility Study (EFS) evaluating the HEMOPURIFIER® in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study is enrollin...